CA Patent

CA2515151A1 — Non-nucleoside reverse transcriptase inhibitors

Assigned to F Hoffmann La Roche AG · Expires 2004-09-02 · 22y expired

What this patent protects

This invention relates to novel pyrazole derivatives of formula (I) wherein R1 to R4 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibits or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds o…

USPTO Abstract

This invention relates to novel pyrazole derivatives of formula (I) wherein R1 to R4 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibits or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula (I) and pharmaceutical compositions of formula (I) admixed with at least one solvent, carrier or excipient. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated (formula I).

Drugs covered by this patent

Patent Metadata

Patent number
CA2515151A1
Jurisdiction
CA
Classification
—
Expires
2004-09-02
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.